HUYABIO announces Hiyasta ™ brand name HBI-8000
Dr. Mireille Gilling, CEO and Executive Chairman of HUYABIO said, “Today’s Hiyasta approval for ATLL came in just 9 months. Our business partnership with Meiji will now bring Hiyasta to patients and provide a much needed public health benefit for this devastating and potentially fatal disease. “
Hiyasta was also submitted to PMDA in March for approval as monotherapy for the treatment of peripheral T cell lymphoma (PTCL). In addition, the ODD designation for Hiyasta in Japan has been formally approved for ATLL and PTCL.
HBI-8000 is an epigenetic immunomodulator approved for the treatment of lymphoma and metastatic breast cancer in China. This oral agent targets class I histone deacetylases (HDAC) and suppresses the expression of the viral oncogene HTLV-I bZIP factor, the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and inflammasome in ATLL cells. Additionally, HBI-8000 can induce latent viral antigen expression, making ATLL cells more sensitive to targeting immune cytotoxicity.
About HUYABIO International
HUYABIO is the leader in accelerating the global development of new opportunities for biopharmaceuticals from China enabling faster, more cost-effective and lower-risk drug development in global markets. Through close collaboration with biopharmaceutical, academic and commercial organizations, he has built the largest Chinaportfolio of sourced compounds covering all therapeutic areas. With offices in the United States, Japan, South Korea, Canada, Ireland and eight strategic locations across China, the company has become a partner of choice in accelerating product development and maximizing value globally. For more information, please visit www.huyabio.com.
Bob goodenow, doctorate
SOURCE HUYABIO International